Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 6,078

Document Document Title
WO/2020/186199A1
Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), ...  
WO/2020/161217A1
The invention relates to 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (LBAT) inhibitory activit...  
WO/2020/076274A3
The present invention is related to unique caffeic acid phenethyl ester (CAPE) analogues, methods for preparation of said molecules, and the usage of said unique molecules in the preparation of a pharmaceutical composition that is to be ...  
WO/2020/131980A1
The invention described herein generally relates to novel therapeutic compounds, and in particular to carbonic anhydrase inhibitors as a narrow spectrum antibiotics against drug resistant bacteria and methods for treating those infection...  
WO/2020/128003A1
The present invention relates to a method of synthesis of compound (I), wherein R1 represents methyl or methyl-d3, thus corresponding to 3-methyl-1,2,4-thiadiazole-5-carbohydrazide or to the methyl-d3 deuterated form thereof. These compo...  
WO/2020/128259A1
The invention relates to the use, as a crosslinking agent for unsaturated polymers, of a polysulphide compound of formula (I) in which: n is a number greater than or equal to 2, Z represents an O atom or the group -N(H)-, and R and R2 ea...  
WO/2020/119616A1
Disclosed are a class of sulfonamide substituted compounds and the use thereof. Specifically, provided are compounds as shown in general formula (I) below. The compounds of the present invention have a selective inhibitory effect on Nav1...  
WO/2020/109902A1
The present disclosure provides a resin blend containing a blend of a phthalonitrile resin and a thiadiazole substituted phthalonitrile compound. The present disclosure also provides an article including a polymerization product of such ...  
WO/2020/099406A1
The present invention relates to herbicidally active thiadiazole derivatives, as well as to processes and intermediates used for the preparation of such derivatives. The invention further extends to herbicidal compositions comprising suc...  
WO/2020/094542A1
The invention relates to 5,6-diphenyl-5,6-dihydro- dibenz[c,e][1,2 ]azaphosphorin and 6-phenyl-6H-dibenzo[c,e] [1,2]thiazin-5,5 dioxide derivatives and similar compounds of the formula (1) as organic electroluminescent materials for use ...  
WO/2020/095161A1
The present invention relates to novel nitrone compounds of formula (I), wherein, A, A1, R1, R2, R3, R4 and n are as defined in the description. The present invention further relates to their preparation and use to protect crops against ...  
WO/2020/062375A1
Disclosed are 1,2,4-thiadiazole compounds, a preparation method therefor and the use thereof. The 1,2,4-thiadiazole compounds as OLED device light-extracting layer materials, can significantly improve the luminous intensity, current effi...  
WO/2020/052509A1
Provided in the present invention are a sulfonamide compound serving as a sodium channel blocker and uses thereof. The compound simultaneously provides dual inhibitory activity with respect to Nav1.7 and Nav1.3 and is applicable as a med...  
WO/2020/051319A1
The present disclosure provides, in part, cyclic sulfamide compounds, pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.  
WO/2020/043866A1
A compound for use in the treatment of a disease ameliorated by the inhibition of Notum of formula (I): (I)  
WO/2020/016434A1
The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection an...  
WO/2020/012423A1
The invention relates to thiadiazine derivatives, or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof, as well as to pharmaceutical compos...  
WO/2020/006294A1
Disclosed herein are methods of treating liver fibrosis by administering calpain inhibitors to subjects in need thereof.  
WO/2019/245448A1
The present invention relates to crystal modifications of 1,1-dioxo-3,3-dibutyl-5-phenyl-7- methylthio-8-(N-{(R)-α-[N-((S)-1-carboxypropyl)carbamoyl]-4 -hydroxybenzyl}carbamoylmethoxy)- 2,3,4,5-tetrahydro-1,2,5-benzothiadiazepine (odevi...  
WO/2019/246513A1
Provided herein are compounds, compositions, and methods useful for inhibiting protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), ...  
WO/2019/234077A1
The invention relates to1,5-benzothiazepine and 1,2,5-benzothiadiazepine derivatives of formula (I). These compounds are bile acid modulators having apical sodium-dependent bile acid transporter (ASBT) and/or liver bile acid transport (L...  
WO/2019/234651A1
A process is described for the preparation of thiadiazole derivatives and more specifically a new synthetic process of compounds having general formula (I) and intermediate compounds having general formula (XVI).  
WO/2019/236890A1
The present disclosure provides compounds and methods useful for inhibiting SARMI and/or treating and/or preventing axonal degeneration. Provided SARMI inhibitors reduce or inhibit binding of NAD+ by SARMI and SARMI inhibitors bind to SA...  
WO/2019/084463A8
The present disclosure is concerned with oxadiazole and thiadiazole analogs that are capable of inhibiting TGF-β and methods of treating cancers such as, for example, multiple myeloma and a hematologic malignancy, and methods of treatin...  
WO/2019/229464A1
There are described compounds of formula (I): (I) and their use as a medicament in the treatment of diseases associated with the abnormal or elevated catabolism of tryptophan, such as, cancer, immunosuppression, viral infection, depressi...  
WO/2019/222146A1
In some embodiments of the invention, inventive compounds (e.g., Formula (I), (IA), (II), and (III), and urolithin derivatives) are disclosed. Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inve...  
WO/2019/222559A1
Methods for testing the effects of therapeutic compound candidates on a phenotypic organoid model is provided. Such a method includes steps of generating the phenotypic organoid model on a high throughput screening platform, treating the...  
WO/2019/217834A1
The invention is directed towards compounds, methods of stimulating myelination, stimulating proliferation of oligodendrocytes (OLs) or stimulating oligodendrocyte precursor cells and methods of treating diseases, disorders or symptoms t...  
WO/2019/216574A1
The present specification relates to a nitrogen-containing compound, a color conversion film comprising same, a backlight unit, and a display apparatus.  
WO/2019/216573A1
The present specification relates to a nitrogen-containing compound, a color conversion film comprising same, a backlight unit, and a display apparatus.  
WO/2019/195751A1
Compounds of formula (I) wherein, R1, R2, R3, R4a, R4b and R5 are described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as...  
WO/2019/193540A1
The invention is directed to substituted heteroaryl derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein A, C, D, L2, L3, R1, R2, R3, R4, R 5, R6, z2, z4, z5, and z6 are as defined herein; or...  
WO/2019/186498A1
Fluoroalkenyl heterocyclic compounds having Formula (I) are described together with agronomic compositions containing said compounds having formula (I) and their use for the control of nematodes in agricultural crops.  
WO/2019/190999A1
Disclosed herein are methods of treating fibrotic disorders by administering compounds selective for CAPN1, CAPN2, and/or CAPN9 such that side effects, off pathway interactions, and/or toxicities are minimized. Such methods may, for exam...  
WO/2019/190885A1
Small molecule calpain modulator compounds, including their pharmaceutically acceptable salts, can be included in pharmaceutical compositions. The compounds can be useful in inhibiting calpain, or competitive binding with calpastatin, by...  
WO/2019/173761A1
Disclosed herein are embodiments of a compound that inhibits c-Abl tyrosine kinase (also referred to herein as "c-Abl"). The compound embodiments described herein are novel c-Abl inhibitors that can bind to c-Abl at an allosteric site an...  
WO/2019/166206A1
The present invention relates to an organic material and to an electronic device comprising the organic material, particularly to an electroluminescent device, particularly to an organic light emitting diode (OLED), wherein the semicondu...  
WO/2019/070709A8
The present invention provides compounds, compositions and methods for treating and/or preventing a flavivirus infection by administering such compounds and compositions.  
WO/2019/139921A1
Selective HDAC inhibitors, and pharmaceutical compositions that include the same, are described herein for the treatment of cancer, immunological diseases, inflammatory diseases, and neurological diseases.  
WO/2019/133813A1
The present invention provides pyrazoles, isoxazoles, isothiazoles, thiadiazoles, and pyridazines according to Formula I as described herein, and pharmaceutically acceptable salts thereof. Pharmaceutical compositions and methods for trea...  
WO/2019/131922A1
The present invention provides a compound that has β2-adrenergic receptor antagonist activity and carbonic anhydrase-inhibitory activity, and that exhibits excellent ocular antihypertensive activity. Specifically provided is a compound ...  
WO/2019/121761A1
The invention relates to the non-therapeutic cosmetic use of at least one compound of formula (I) as defined below, as an agent for bleaching, lightening and/or depigmenting keratin materials, especially the skin. The invention also rela...  
WO/2019/098886A1
Novel linear oligoarylsilanes and a method of producing same are claimed. Novel linear oligoarylsilanes having general formula (I), where Ar signifies identical or different arylene radicals or heteroarylene radicals selected from the gr...  
WO/2019/084463A1
The present disclosure is concerned with oxadiazole and thiadiazole analogs that are capable of inhibiting TGF-β and methods of treating cancers such as, for example, multiple myeloma and a hematologic malignancy, and methods of treatin...  
WO/2019/079860A1
The present invention relates to an optical sensing element for detection of a narcotic, the optical sensing element comprising a fluorescent sensing compound provided on a substrate, wherein emission of the fluorescent sensing compound ...  
WO/2018/064119A8
Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.  
WO/2019/070709A1
The present invention provides compounds, compositions and methods for treating and/or preventing a flavivirus infection by administering such compounds and compositions.  
WO/2019/060906A1
The present invention provides methods and compositions for treating a CNS disease, disorder or injury, (e.g., a CNS demyelinating disease). The present invention provides methods and compositions for preserving or protecting neuroaxonal...  
WO/2019/053617A1
The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to FormµLa (I): wherein R, R1,P, X, Y, and Z are as defined herein; or a pharmaceutically acceptable salt ...  
WO/2019/043139A1
A compound of formula (I): which inhibits the activity of one or more KATs of the MYST family, i.e., TIP60, KAT6B, MOZ, HBO1 and MOF.  

Matches 1 - 50 out of 6,078